All News
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults
As the population ages globally, rheumatologists are caring for an increasingly older patient population more than ever before. In RA alone, nearly 40 percent of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental question: do we really know how best to treat older adults with rheumatic diseases?
Read Article
GLP-1 Receptor Agonists: Impacts Beyond Metabolism?
The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.
Read Article
NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4
Richard Conway RichardPAConway ( View Tweet)
Many GLP-1 drugs in the pipeline for management in #OA
#ACR25 @rheumnow https://t.co/y3UCp0CcUb
Bella Mehta bella_mehta ( View Tweet)
Semaglitide did help in weight loss and decrease in pain in knee OA
https://t.co/240sR5An3m
#acr25 @rheumnow
Question is that is the pain decrease is secondary to weight loss or an independent effect? https://t.co/R2v5YDP3A5
Links:
Bella Mehta bella_mehta ( View Tweet)
#ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
List of GLP1 agonists approved currently..would they have effects in #OA
Session title is should we gave them to everyone?
#ACR25 @RheumNow https://t.co/dXwB6Jkg8C
Bella Mehta bella_mehta ( View Tweet)
HOPE for Pts w #fibromyalgia #FM
#Transcutaneous #electrical #nerve #stimulation + #physio
Is
Better than #PT alone
#Pragmatic #cluster #randomized #trial
Answered impt question
Does #TENS help Pts w #fibro
Too ba noTENS sham
Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN
Janet Pope Janetbirdope ( View Tweet)
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica
Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR).
https://t.co/CLmCdBXiOf https://t.co/z20nWd2NSM
Dr. John Cush RheumNow ( View Tweet)
Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube
@alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#0852 LEVI-04, a novel p75NTR-Fc fusion protein, significantly reduces MRI bone marrow lesions in knee #OA 🦵📉
Phase II RCT (n=518): dose-dependent BML reduction (p<0.001) + correlated improvement in pain & function. Promising structure-modifying OA therapy
@RheumNow #ACR25 https://t.co/huA8OaFGSd
Mrinalini Dey DrMiniDey ( View Tweet)
In this ph2 trial of LEVI-04 for knee #osteoarthritis,
At wk 20, LEVI-04 ⬇️ bone marrow lesions (BML), greater ⬇️ in BML area even w/ higher KL grades
Promising treatment.
#ACR25 @RheumNow Abs0852 #ACRBest https://t.co/MrmLPlFiDs
Links:
sheila RHEUMarampa ( View Tweet)
Summary take home points by Dr Highland
1. PAH and PH-ILD are associated with high mortality in patients with SARDs
2. Multimodal and early screening is recommended
3. “It takes a village” work with Pulm and Cardiology colleagues
@RheumNow #ACR2025 https://t.co/Xa7TecMOIe
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
In the #ACR25 Great AI Debate, @RADoctor and @JYazdanyMD prepared independently, but in consecutive moments agree (in a very illustrative way):
guardrails - they need to happen
@RheumNow https://t.co/ccLLC3adxG
Links:
David Liew drdavidliew ( View Tweet)
What is better in #PsA post #TNFi?
#RCT of #secukinumab v #ustekinumab
The big 🤔? #IL17Ai vs IL12/23i
🏆 #Cosentyx
✈️✅PASI
⚜️✅ACR50
Will H2H studies change our #prescribing?🤷♀️
#rheums Rx #IL17i>#IL12i/23i vs #derms
#ACRBest #ACR25 @RheumNow @ACRheum abst#LB06 https://t.co/RpC8ymDc7H
Janet Pope Janetbirdope ( View Tweet)
🎥 LIVE from #ACR25
Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways.
Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live.
Save the time. Be part of https://t.co/xn4yUta9Da
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
What is the #frequency of #CTD #ILD in #USA?
Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts
56-65 yrs, 3/4 F
?under ascertained #RA-ILD - low % but #SSc-ILD approx 16% clinically relevant
Same as Ont, Canada #SSc-ILD %
Not rare
#ACR25 @RheumNow @ACRheum
Abst#0154 https://t.co/imfSyOtYpC
Links:
Janet Pope Janetbirdope ( View Tweet)
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMbrQnq8YG
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
High prevalence of sleep related symptoms in PsA pts!
-Snoring 53%
-Morning fatigue 68%
-Obstructive Sleep Apnea in 50%
14% mild 19% moderate 17% severe
Estimated prevalence 36%
No correlation between OSA and PsA disease activity or comorbidities
But small cohort! https://t.co/VKe7qcHIRm
Aurelie Najm AurelieRheumo ( View Tweet)
